Carcinogenesis, Vol. 23, No. 5, 683-686,
May 2002
© 2002 Oxford University Press
COMMENTARY |
Genetics and new approaches to cancer therapy
Ludwig Institute for Cancer Research, Department of Medicine, Center for Molecular Genetics, and Cancer Center, University of California at San Diego, La Jolla, CA 92093-0660, USA
Email: wcavenee@ucsd.edu
Abbreviations: CDDP, cis-diamminedichloroplatinum(II); EGF, epidermal growth factor; GBM, glioblastoma multiforme; PARP, poly(ADP-ribose) polymerase.
 |
Introduction |
|---|
The past two decades have been golden years for the genetics of cancer. It has become clear through the work of countless laboratory groups that both inherited and sporadic cancers arise through defects or misregulations of their genomes. Several dozen dominantly acting oncogenes have been identified, shown to be deregulated in human tumors and to positively influence one or another aspect of tumor development or behavior in experimental systems. A smaller, but still substantial, number of recessively mutated tumor suppressor genes have also been identified which, in defective form, predispose to malignancy, both in people and in genetically manipulated rodent models. The cartography of the order, accumulation and interactions of genetic lesions during tumor initiation and progression has reasonable detail for many human tumor types. Such information is proving to be tremendously valuable in diagnosis and in grouping patients into prognostic categories. There is every reason to believe that the
|
The EGFR gene is often altered in malignant gliomas |
|---|
|
 EGFR is predominantly expressed on the cell surface and is constitutively active in glioma cells
|
|---|
|
Enhancement of tumorigenicity by EGFR
|
|---|
|
EGFR confers drug resistance to glioma cells
|
|---|
|
Targeting EGFR kinase with small molecule inhibitors
|
|---|
|
Antibody therapy directed against EGFR
|
|---|
|
Conclusions |
|---|
|
Notes |
|---|
|
Acknowledgments |
|---|
|
References |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. A. Bax, N. Gaspar, S. E. Little, L. Marshall, L. Perryman, M. Regairaz, M. Viana-Pereira, R. Vuononvirta, S. Y. Sharp, J. S. Reis-Filho, et al. EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines Clin. Cancer Res., September 15, 2009; 15(18): 5753 - 5761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Arwert, S. Hingtgen, J.-L. Figueiredo, H. Bergquist, U. Mahmood, R. Weissleder, and K. Shah Visualizing the Dynamics of EGFR Activity and Antiglioma Therapies In vivo Cancer Res., August 1, 2007; 67(15): 7335 - 7342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H. Huang, A. Mukasa, R. Bonavia, R. A. Flynn, Z. E. Brewer, W. K. Cavenee, F. B. Furnari, and F. M. White Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma PNAS, July 31, 2007; 104(31): 12867 - 12872. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Valadon, J. D. Garnett, J. E. Testa, M. Bauerle, P. Oh, and J. E. Schnitzer Screening phage display libraries for organ-specific vascular immunotargeting in vivo PNAS, January 10, 2006; 103(2): 407 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Gilbertson, D. A. Hill, R. Hernan, M. Kocak, R. Geyer, J. Olson, A. Gajjar, L. Rush, R. L. Hamilton, S. D. Finkelstein, et al. ERBB1 Is Amplified and Overexpressed in High-grade Diffusely Infiltrative Pediatric Brain Stem Glioma Clin. Cancer Res., September 1, 2003; 9(10): 3620 - 3624. [Abstract] [Full Text] [PDF]
|
|